Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Ppublish 1020 citations
Electronic publication date
November 15, 2011

View on Pubmed.gov 21930769 | View on doi.org 10.1084/jem.201...

Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Search for publications in this journal J Exp Med - 208(10):1989-2003

Abstract

Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shapes tumor immunogenicity. We previously reported that type I interferon (IFN-α/β) plays a central role in this process and that hematopoietic cells represent critical targets of type I IFN's actions. However, the specific cells affected by IFN-α/β and the functional processes that type I IFN induces remain undefined. Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting. Using mixed bone marrow chimeric mice, we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells. In contrast, mice depleted of NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these tumors normally. Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection.

References

J Exp Med. 2009 Jul 6;206(7):1589-602

J Immunol. 2009 Jul 15;183(2):1099-109

J Immunol. 2009 Aug 15;183(4):2286-93

J Exp Med. 2009 Dec 21;206(13):3115-30

Cited by 1020 citations (total)

Journal Article

Genuine Immunomodulation With dSLIM.

Electronic publication date June 25, 2014

Search for publications in this journal Mol Ther Nucleic Acids

Kerstin Kapp [...] Burghardt Wittig et al.

Toll-like receptors are sensing modulators of the innate immune system. One member of this protein family, Toll-like receptor (TLR)-9, is...

Journal Article Research Support, N.I.H., Extramural

Host STAT2/type I interferon axis controls tumor growth.

Electronic publication date December 23, 2014

Search for publications in this journal Int J Cancer

Chanyu Yue [...] Ana M Gamero et al.

The role of STAT2 in mediating the antigrowth effects of type I interferon (IFN) is well-documented in vitro. Yet evidence...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances